Lantern Pharma is trading 10.96% higher at $0.95 on October 5, 2026, following a sharp recent decline; no confirmed company-specific catalyst for the rebound was identified.
- The S&P 500 is up 0.69% and the Nasdaq is up 1.08%, which may support sentiment but does not establish the reason for Lantern Pharma’s move.
- A September 30 registered direct offering raised approximately $4 million gross at $1.09 per share or pre-funded warrant; available reporting does not tie it directly to the October 5 gain.